Neoadjuvant chemoradiotherapy followed by esophagectomy vs. surgery alone in the treatment of resectable esophageal squamous cell carcinoma.

Meta-analysis of postoperative efficacy in patients receiving chemoradiotherapy followed by surgery for resectable esophageal carcinoma. Diagn Pathol (2014) 0.81

Current status of and perspectives regarding neoadjuvant chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Surg Today (2015) 0.75

Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer. Cancer Med (2016) 0.75

Histone deacetylase inhibitor trichostatin A enhances the antitumor effect of the oncolytic adenovirus H101 on esophageal squamous cell carcinoma in vitro and in vivo. Oncol Lett (2017) 0.75

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med (1996) 9.85

Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med (1992) 7.40

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol (2008) 7.01

INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol (2002) 6.74

Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol (2001) 6.07

Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol (2005) 5.40

Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med (1997) 4.94

A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol (2011) 4.22

Surgical therapy of oesophageal carcinoma. Br J Surg (1990) 3.94

Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg (1994) 3.80

Transhiatal esophagectomy: clinical experience and refinements. Ann Surg (1999) 3.24

Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann Thorac Surg (1991) 3.00

Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg (2000) 2.86

Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology (1991) 2.54

Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg (2004) 2.47

Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. Ann Surg (1995) 2.27

Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer (2003) 2.23

Should en bloc esophagectomy be the standard of care for esophageal carcinoma? Ann Surg (2001) 2.21

Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg (1993) 2.18

A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer (1994) 2.17

Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg (2004) 2.12

Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg (2000) 1.98

Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg (2002) 1.96

A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg (1997) 1.61

En bloc esophagectomy improves survival for stage III esophageal cancer. J Thorac Cardiovasc Surg (1997) 1.61

A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology (1994) 1.55

Esophagogastrectomy for carcinoma of the esophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg (1997) 1.53

A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol (2004) 1.53

The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg (2000) 1.48

Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus. World J Surg (1997) 1.40

Preoperative chemotherapy for localized squamous cell carcinoma of the esophagus? We should go back to the drawing board! Ann Surg Oncol (2012) 1.40

Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J Surg (2007) 1.30

Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. Br J Cancer (2008) 1.19

Histopathologic characteristics of early stage esophageal carcinoma. A comparative study with gastric carcinoma. Cancer (1992) 1.18

Carcinoma of the esophagus. Prognostic significance of histologic type. J Thorac Cardiovasc Surg (1995) 1.12

Nodal metastasis and sites of recurrence after en bloc esophagectomy for adenocarcinoma. Ann Thorac Surg (1994) 1.11

Surgery for cancer of the esophagus. Semin Oncol (1994) 1.08

Patterns of recurrence after curative resection for carcinoma of the thoracic part of the esophagus. Surg Gynecol Obstet (1983) 1.01

Significance of extended systemic lymph node dissection for thoracic esophageal carcinoma in Japan. Recent Results Cancer Res (2000) 0.91

Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection. Ann Surg (2004) 0.91

Pattern of recurrence after extended esophagectomy for squamous cell carcinoma of the esophagus. Hepatogastroenterology (2003) 0.90

Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report. Oncol Rep (2005) 0.89

Extended surgery for cancer of the esophagus and gastroesophageal junction. J Surg Res (2004) 0.89

Localization of recurrent disease after extended lymph node dissection for carcinoma of the thoracic esophagus. J Am Coll Surg (1996) 0.87

Exclusive radical surgery for esophageal adenocarcinoma. Cancer (2001) 0.87

Concurrent preoperative chemotherapy and radiation therapy in localized esophageal adenocarcinoma. Cancer (1992) 0.86

Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients. Oncol Rep (2012) 0.82

The role of adjuvant chemotherapy for localized squamous cell esophageal cancer: current Japanese standard and the unending role of the drawing board. Ann Surg Oncol (2012) 0.76